ProRx Pharma, the leading health and wellness 503B outsourcing facility, has announced the availability of its innovative oral NAD+ formulation.
This advancement introduces a new, convenient option for medical clinics and wellness providers seeking to support cellular energy, DNA repair and long-term vitality in their patients without relying on daily injectable protocols.
NAD+ is essential for cellular energy, DNA repair and longevity.
Declining NAD+ (nicotinamide adenine dinucleotide) levels can contribute to fatigue, slower recovery and cognitive decline.
ProRx Pharma's exclusive oral delivery system provides the traditional benefits of NAD+ without the burden of maintaining daily injection protocols.
Through this liquid delivery system, each NAD+ dose provides reliable stability and consistency.
"This technology represents a significant milestone in compounding innovation," said Kurt Lunkwitz, Chief Operating Officer at ProRx Pharma.
"Our oral NAD+ formulation offers a convenient alternative to injectable options, giving healthcare providers a way to deliver high-quality cellular support that aligns with today's performance-focused wellness programmes."
A new standard in NAD+ delivery
ProRx's liquid NAD+ marks a meaningful advance in compounding science, providing all of the potential clinical benefits of traditional NAD+ without the invasiveness, higher cost, in-clinic time requirements, sterility risks and limited scalability associated with injectable therapies.
Providers can now offer NAD+ support that fits seamlessly into telemedicine, maintenance therapy and high-performance wellness protocols.
ProRx's oral NAD+ is offered in a 1 mL daily-use ampule, compounded under strict USP <795> and cGMP standards in the company's FDA-registered 503B facility.
Each batch undergoes third-party potency, bioburden, particle size and water-activity testing—ensuring reliability, stability and performance.